Analyst Scoreboard: 5 Ratings For Clene
In the preceding three months, 5 analysts have released ratings for Clene (NASDAQ:CLNN), presenting a wide array of perspectives from bullish to bearish.The table below summarizes their recent ratings
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright analyst Joseph Pantginis maintains $Clene(CLNN.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 37.3% and a to
Express News | Clene Inc.: More Than 650 Patient Years of Cnm-AU8 Treatment Exposure Without Any Identified Safety Signals
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results With CNM-Au8 30 Mg Treatment From the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)Average of 28% NfL reduction observed in an
Clene Presents Extended Survival Data Through 3.5 Years And New NfL Responder Results With CNM-Au8 30 Mg Treatment From The HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)Average of 28% NfL reduc
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Shares of Oracle Corporation (NYSE:ORCL) rose sharply in today's pre-market trading after the company reported fourth-quarter financial results.Oracle posted weaker-than-expected earnings for its fisc
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharma
Clene Shareholders Approve Expansion and Governance Changes
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)
Express News | Clene's NIH-Funded ALS Program For CNM-Au8 Expands Enrollment By 80%, Launches Data Collection In June
Express News | Clene Inc. - First Patient, First Visit Is Planned for Early June 2024
Express News | Clene Provides Update on Its Nih-Funded Expanded Access Program for Cnm-AU8® in ALS (Act-Eap)
Analyst Scoreboard: 6 Ratings For Clene
6 analysts have shared their evaluations of Clene (NASDAQ:CLNN) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent
Benchmark Co. Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $5
Benchmark Co. analyst Bruce Jackson maintains $Clene(CLNN.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 31.2% and a total a
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Biogen (BIIB) and Clene (CLNN)
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage bioph
Clene First Quarter 2024 Earnings: Misses Expectations
Clene(CLNN.US) 10% Shareholder Sells US$10,563.8 in Common Stock
$Clene(CLNN.US)$ 10% Shareholder General Resonance LLC sold 26,000 shares of common stock on Apr 30, May 1, 2024 at an average price of $0.4063 for a total value of $10,563.8.Source: Announcement What
Clene Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Clene Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
No Data